Diansong Zhou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3675505/publications.pdf

Version: 2024-02-01

58 papers	1,072 citations	516710 16 h-index	454955 30 g-index
58 all docs	58 docs citations	58 times ranked	1337 citing authors

#	Article	IF	Citations
1	Acalabrutinib CYP3Aâ€mediated drugâ€“drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. British Journal of Clinical Pharmacology, 2022, , .	2.4	4
2	Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib. Pharmaceutical Research, 2022, , 1.	3.5	1
3	Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. Pharmaceutics, 2022, 14, 1010.	4.5	7
4	Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal Impairment. Journal of Pharmaceutical Sciences, 2021, 110, 438-445.	3.3	3
5	Evolving drug regulatory landscape in China: A clinical pharmacology perspective. Clinical and Translational Science, 2021, 14, 1222-1230.	3.1	11
6	Population pharmacokinetics and exposureâ€“response of selumetinib and its Nâ€desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. Cancer Chemotherapy and Pharmacology, 2021, 88, 189-202.	2.3	7
7	Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. Cancer Chemotherapy and Pharmacology, 2021, 88, 451-464.	2.3	6
8	Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drugâ€Drug Interactions and Pediatric Dose Regimens. Journal of Clinical Pharmacology, 2021, 61, 1493-1504.	2.0	7
9	Selecting the dosage of ceftazidimeâ€“avibactam in the perfect storm of nosocomial pneumonia. European Journal of Clinical Pharmacology, 2020, 76, 349-361.	1.9	9
10	Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1030-1038.	1.5	5
11	Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 419-427.	2.5	13
12	A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2â^' Primary Breast Cancer. Clinical Cancer Research, 2020, 26, 4242-4249.	7.0	29
13	Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 29-36.	0.6	3
14	Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling. European Journal of Pharmaceutical Sciences, 2019, 139, 105061.	4.0	23
15	Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 65-74.	1.8	7
16	Evaluation of the Drugâ€“Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, <scp>ACP</scp>â€5862, Using a <scp>Physiologicallyâ€Based Pharmacokinetic</scp> Modeling Approach. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 489-499.	2.5	36
17	Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Communityâ€Acquired Pneumonia Treated With Ceftaroline Fosamil. Clinical Pharmacology in Drug Development, 2019, 8, 682-694.	1.6	6
18	Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies. Clinical Pharmacology and Therapeutics, 2019, 105, 1303-1320.	4.7	9

#	Article	IF	Citations
19	Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 100-107.	2.5	13
20	Population Pharmacokinetic and Exposureâ€Response Analysis of Selumetinib and Its Nâ€desmethyl Metabolite in Patients With Nonâ€Small Cell Lung Cancer. Journal of Clinical Pharmacology, 2019, 59, 112-122.	2.0	4
21	Efficacy and Safety Exposureâ€Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients. Clinical Pharmacology and Therapeutics, 2019, 105, 1492-1500.	4.7	12
22	Ceftaroline fosamil doses and breakpoints forStaphylococcus aureusin complicated skin and soft tissue infections. Journal of Antimicrobial Chemotherapy, 2019, 74, 425-431.	3.0	31
23	Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clinical Pharmacokinetics, 2019, 58, 615-625.	3.5	18
24	Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations. Clinical Pharmacology and Therapeutics, 2019, 105, 229-241.	4.7	51
25	Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children. Clinical Pharmacology and Therapeutics, 2018, 104, 188-200.	4.7	51
26	Population pharmacokinetics of the MEK inhibitor selumetinib and its active Nâ€desmethyl metabolite: data from 10 phase I trials. British Journal of Clinical Pharmacology, 2018, 84, 52-63.	2.4	12
27	Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. Journal of Clinical Pharmacology, 2018, 58, 485-493.	2.0	14
28	Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo Simulation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	1
29	Population Pharmacokinetic Modeling With Enterohepatic Circulation for AZD3241 in Healthy Subjects and Patients With Multiple System Atrophy. Journal of Clinical Pharmacology, 2018, 58, 1452-1460.	2.0	9
30	Development of a physiologically based pharmacokinetic model to predict the effects of flavinâ€containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharmaceutics and Drug Disposition, 2017, 38, 389-393.	1.9	8
31	Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 539-546.	1.5	7
32	Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting Âμ-Opioid Receptor Antagonist. Clinical Pharmacokinetics, 2017, 56, 573-582.	3.5	12
33	Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine. Journal of Clinical Pharmacology, 2017, 57, 1258-1267.	2.0	1
34	Population Exposureâ€Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioidâ€Induced Constipation. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 705-711.	2.5	2
35	Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis. Journal of Clinical Pharmacology, 2017, 57, 336-344.	2.0	17
36	Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects. Clinical Therapeutics, 2016, 38, 2555-2566.	2.5	3

#	Article	IF	Citations
37	Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 6252-6259.	3.2	44
38	Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 475-483.	2.5	62
39	Simulation and Prediction of the Drugâ€Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 250-257.	2.5	34
40	The effect of quinidine, a strong Pâ€glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. Journal of Clinical Pharmacology, 2016, 56, 497-505.	2.0	25
41	Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol. Journal of Clinical Pharmacology, 2016, 56, 1019-1027.	2.0	14
42	Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Journal of Clinical Pharmacology, 2015, 55, 1248-1255.	2.0	12
43	Physiologically based pharmacokinetic modeling to predict complex drugâ€“drug interactions: a case study of AZD2327 and its metabolite, competitive and timeâ€dependent CYP3A inhibitors. Biopharmaceutics and Drug Disposition, 2015, 36, 507-519.	1.9	8
44	Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. Journal of Clinical Pharmacology, 2015, 55, 1024-1030.	2.0	6
45	Pharmacokinetics, metabolism and excretion of [¹⁴C]-lanicemine (AZD6765), a novel low-trappingN-methyl-<scp>d</scp>-aspartic acid receptor channel blocker, in healthy subjects. Xenobiotica, 2015, 45, 244-255.	1.1	7
46	Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 404-410.	1.5	6
47	Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharmaceutics and Drug Disposition, 2014, 35, 341-352.	1.9	61
48	Metabolism of a G Protein-Coupled Receptor Modulator, Including Two Major 1,2,4-Oxadiazole Ring-Opened Metabolites and a Rearranged Cysteine-Piperazine Adduct. Drug Metabolism and Disposition, 2012, 40, 1151-1163.	3.3	13
49	A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA_A receptor modulator â€“ an in vitro and in vivo comparison. British Journal of Clinical Pharmacology, 2012, 74, 98-108.	2.4	12
50	In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction, and Differential Kinetics. Drug Metabolism and Disposition, 2011, 39, 703-710.	3.3	121
51	Liquid chromatographyâ€“tandem mass spectrometry method for measurement of nicotine N-glucuronide: A marker for human UGT2B10 inhibition. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 964-971.	2.8	7
52	In Vitro and In Vivo Metabolism of a Selective Î´-Opioid Receptor. Drug Metabolism and Disposition, 2011, 39, 1883-1894.	3.3	8
53	In vitrometabolism of Î±7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for itsN-oxide metabolite. Xenobiotica, 2011, 41, 232-242.	1.1	11
54	Expression and Characterization of Dog Cytochrome P450 2A13 and 2A25 in Baculovirus-Infected Insect Cells. Drug Metabolism and Disposition, 2010, 38, 1015-1018.	3.3	19

#	Article	IF	Citations
55	Role of Human UGT2B10 inN-Glucuronidation of Tricyclic Antidepressants, Amitriptyline, Imipramine, Clomipramine, and Trimipramine. Drug Metabolism and Disposition, 2010, 38, 863-870.	3.3	43
56	In vitroassessment of metabolic drugâ€“drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450enzyme identification, inhibition, and induction studies. Xenobiotica, 2010, 40, 721-729.	1.1	12
57	Rapid Classification of CYP3A4 Inhibition Potential Using Support Vector Machine Approach. Letters in Drug Design and Discovery, 2007, 4, 192-200.	0.7	14
58	COMPARISON OF METHODS FOR THE PREDICTION OF THE METABOLIC SITES FOR CYP3A4-MEDIATED METABOLIC REACTIONS. Drug Metabolism and Disposition, 2006, 34, 976-983.	3.3	81